Skip to content
TriangleGet started
← Full study record

NCT03107988 · MORE INFO

Limitations, agreements, and source contact

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) · Source last updated 2025-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
nantops@chla.usc.edu
organization
New Approaches to Neuroblastoma Therapy
phone
3233615687
title
NANT Medical Director
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
nantops@chla.usc.edu
organization
New Approaches to Neuroblastoma Therapy
phone
3233615687
title
NANT Medical Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice